As reported in a research article, 638 patients were implanted with an epic stented tissue valve.The rates of permanent pacemaker implant at 30-day, after 30-day, and at 5-year were (b)(6) respectively.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device was received for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.
|
Reference manufacturer report number: 3008452825-2020-00497.The article "early and late pace-maker implantation after transcatheter and surgical aortic valve replacement" was reviewed.This research article is a retrospective multi-center experience to evaluate the incidence and predictors of early and late permanent pacemaker (ppm) implantation after transcatheter aortic valve replacement (tavr) and surgical aortic valve replacement (savr) and its impact on long-term mortality.Accurate neo, corevalve, engager, evolut r/pro, lotus, portico, sapien 3, sapien xt, aspire, biocor/epic, freedom solo, hancock ii, inspiris resilia, mitroflow/crown, mosaic, perimount magna ease, soprano, and trifecta were associated to the study.There is no allegation of malfunction of the abbott devices.The article concluded that although the risk of 30-day ppm implantation is higher after tavr compared to savr, late (>30 days) ppm implantation was comparable with these treatment methods.Ppm implantation within 30 days did not affect late survival.The primary author of the article is fausto biancari md, phd, heart and lung center, helsinki university hospital with the email: (b)(6).
|